Recap: Candel Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Candel Therapeutics (NASDAQ:CADL) reported its Q3 earnings, missing estimated earnings by 52.63% with an EPS of $-0.29 versus an estimate of $-0.19. Revenue was down $31 thousand from the same period last year. Despite missing on EPS last quarter, the share price increased by 8.49% the next day.
November 09, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Candel Therapeutics' Q3 earnings missed estimates significantly, which could negatively impact the stock price. However, a similar miss last quarter led to a share price increase.
Candel Therapeutics' significant earnings miss could lead to a decrease in investor confidence and a potential drop in the stock price. However, it's important to note that a similar miss in the previous quarter led to an increase in the share price, indicating that investors may have different expectations for the company.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100